ArticleACS omega2022
Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 29 citations in OpenAlex.
- Selective cytotoxicity of [Cu(theophylline)(HRSC advances · 2026Article
- Article
- Rational Design of Diphenylamino-Thiazole Donor-π-Acceptor Schiff Base Chromophores: Solvatochromic Fluorescence, TD-DFT Insights, and Cytotoxic Activity.Journal of fluorescence · 2026Article
- DNA/BSA binding, antidiabetic and antioxidant studies of copper(ii) complexes derived fromRSC advances · 2026Article
- Regioselective synthesis, structural investigation and binding behavior of 6-aroyl-7-aryl-5-methyl-4,7-dihydro-[1,2,4]triazolo[1,5-RSC advances · 2026Article
- Homoleptic complexes of titanium(iv) fused with O^N^O Schiff base derivatives: design, BSA-DNA interaction, molecular docking, DFT and cytotoxicity.RSC advances · 2025Article
- Multicomponent catalyst-free regioselective synthesis and binding studies of 3-aroyl-2-methylimidazo[1,2-RSC advances · 2025Article
- Mixed-ligand copper(ii)-diimine complexes of 3-formylchromone-RSC advances · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The isolated copper(II) complex [CuL(
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.